Aryan Kia Roghani, Ricardo Isaiah Garcia, Ali Roghani, Aananya Reddy, Sachi Khemka, Ruhananhad P Reddy, Vasanthkumar Pattoor, Michael Jacob, P Hemachandra Reddy, Ujala Sehar
The administration of promising medications for the treatment of neurodegenerative disorders (NDDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) is significantly hampered by the blood-brain barrier (BBB). Nanotechnology has recently come to light as a viable strategy for overcoming this obstacle and improving drug delivery to the brain. With a focus on current developments and prospects, this review article examines the use of nanoparticles to overcome the BBB constraints to improve drug therapy for AD The potential for several nanoparticle-based approaches, such as those utilizing lipid-based, polymeric, and inorganic nanoparticles, to enhance drug transport across the BBB are highlighted...
April 12, 2024: Ageing Research Reviews